NCT03313778
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Must have solid malignancy known to be microsatellite instability (MSI)-high or mismatch repair (MMR)-deficient
Exclusions: Active central nervous system metastases and/or carcinomatous meningitis
https://ClinicalTrials.gov/show/NCT03313778